Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges.

MLA

Schrom, John, et al. “Field Assessment of BinaxNOW Antigen Tests as COVID-19 Treatment Entry Point at a Community Testing Site in San Francisco during Evolving Omicron Surges.” PloS One, vol. 18, no. 3, Mar. 2023, p. e0283576. EBSCOhost, https://doi.org/10.1371/journal.pone.0283576.

APA

Schrom, J., Marquez, C., Wang, C.-Y., Saxena, A., Mitchell, A. M., Ribeiro, S., Pilarowski, G., Nakamura, R., Rojas, S., Black, D., Contreras Oseguera, M. G., Diaz, E. C., Payan, J., Rojas, S., Jones, D., Tulier-Laiwa, V., Zavaleta, A., Martinez, J., Chamie, G., … Havlir, D. V. (2023). Field assessment of BinaxNOW antigen tests as COVID-19 treatment entry point at a community testing site in San Francisco during evolving omicron surges. PloS One, 18(3), e0283576. https://doi.org/10.1371/journal.pone.0283576

Chicago

Schrom, John, Carina Marquez, Chung-Yu Wang, Aditi Saxena, Anthea M Mitchell, Salu Ribeiro, Genay Pilarowski, et al. 2023. “Field Assessment of BinaxNOW Antigen Tests as COVID-19 Treatment Entry Point at a Community Testing Site in San Francisco during Evolving Omicron Surges.” PloS One 18 (3): e0283576. doi:10.1371/journal.pone.0283576.